Fig. 1

IKZF1 mutation in AML. (A) The distribution of IKZF1 mutations, which were identified in our cohort, on the protein. The nonsense or frameshift mutation was marked as red, while the missense mutation was marked as blue. (B, C) The OS (B) and RFS (C) of IKZF1^WT and IKZF1^MUT groups in our AML cohort. (D, E) The influence of IKZF1 mutation burden on the prognosis of AML was studied, and the OS (D) as well as RFS (E) of IKZF1^WT, IKZF1^MUT with VAF > 0.20, and IKZF1^MUT with VAF ≤ 0.20 groups are shown. (F) The difference of additional mutations distribution in IKZF1^WT and IKZF1^MUT groups, and the percentage of each gene mutation is exhibited. (G) The distribution of frequent AML-associated gene mutations in IKZF1^WT and IKZF1^MUT groups, and the count as well as percentage of each gene mutation are shown. (H, I) The prognostic role of combined IKZF1 and SF3B1 mutations on AML was investigated, and the OS (H) as well as RFS (I) of AML with different IKZF1 or SF3B1 mutated status are exhibited